← Human Trials & Peer-Reviewed Studies
Effects of mealtime insulin aspart and bedtime NPH insulin on postprandial inflammation and endothelial cell function in patients with type 2 diabetes
Plain-language guide to PMID 21518259 (2011): randomized and parallel-group clinical trial study of Insulin Aspart and NPH Insulin (isophane).
Key Facts
- PMID
- 21518259
- Journal
- Basic & clinical pharmacology & toxicology
- Year
- 2011
- Study type
- Clinical Trial
- Authors
- Bladbjerg EM et al. (4 authors)
- DOI
- 10.1111/j.1742-7843.2011.00711.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Aspart and NPH Insulin (isophane) in this clinical trial publication.
Acute hyperglycaemia exerts deleterious effects on the arterial wall.
This was tested in a parallel, controlled study on well-controlled patients with type 2 diabetes randomly assigned to bedtime Neutral Protamine Hagedorn (NPH) insulin (n = 41) or mealtime insulin aspart (n = 37).
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and parallel-group study.
Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Insulin Aspart group and the comparison group ran side by side rather than switching.
What Was Measured
This was tested in a parallel, controlled study on well-controlled patients with type 2 diabetes randomly assigned to bedtime Neutral Protamine Hagedorn (NPH) insulin (n = 41) or mealtime insulin aspart (n = 37).
PubMed files the paper under topics including Biomarkers, Cell Adhesion Molecules, Diabetes Mellitus, Type 2, Endothelial Cells, Food Deprivation, Inflammation and Insulin Aspart.
What This Means in Plain Language
The paper is a randomized and parallel-group study of Insulin Aspart and NPH Insulin (isophane).
The publication is from 2011 (Basic & clinical pharmacology & toxicology), a journal based in England.
More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.
Our Notes on the Compounds
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.